Research Index
Thymopoietin Research Index
PSI surfaces 50 peer-reviewed studies on Thymopoietin, prioritized by evidence strength: human clinical research first, then animal studies. The full historical archive is linked below on PubMed.
50 studies
Should Bremelanotide Be Considered for the Treatment of Sexual Arousal and Desire Disorders in Men?
Pfaus JG, Balon R
J Clin Psychopharmacol·2026·Animal·PubMed →
Practical considerations and emerging approaches for the management of vasomotor and sexual symptoms in breast cancer patients on endocrine therapies.
Fuhrman J, Yun J, Indorf A
Expert Rev Clin Pharmacol·2025·Human·Sexual Health·PubMed →
Gap in Sexual Dysfunction Management Between Male and Female Patients Seen in Primary Care: An Observational Study.
Stanley EE, Pfoh E, Lipold L et al.
J Gen Intern Med·2025·Human·Sexual Health·PubMed →
Strategies for Treating Sexual Health Concerns After Breast and Gynecologic Cancer.
Mihulka O, Curran M, Narasimhan RM et al.
J Minim Invasive Gynecol·2025·Animal·PubMed →
FDA-approved drugs as potential covalent inhibitors of key SARS-CoV-2 proteins: an in silico approach.
Serilmez M, Abuelrub A, Erol I et al.
Turk J Biol·2025·Animal·PubMed →
A biodegradable suction patch for sustainable transbuccal peptide delivery.
Krupke H, Zoratto N, Rabut L et al.
J Control Release·2025·Animal·PubMed →
Female Syrian hamster analyses of bremelanotide, a US FDA approved drug for the treatment of female hypoactive sexual desire disorder.
Borland JM, Kohut-Jackson AL, Peyla AC et al.
Neuropharmacology·2025·Animal·PubMed →
Melanocortin Receptor Agonist Bremelanotide Induces Cell Death and Growth Inhibition in Glioblastoma Cells via Suppression of Survivin Expression.
Suzuki S, Kitanaka C, Okada M
Anticancer Res·2024·Animal·PubMed →
First-time orgasm in a young man with lifelong anorgasmia after flibanserin use: a case report.
Saffati G, Naeem T, Kaaki B et al.
Sex Med·2023·Human·PubMed →
Expression of Concern: Salvage of Sildenafil Failures With Bremelanotide: A Randomized, Double-Blind, Placebo Controlled Study.
Safarinejad MR, Hosseini SY
J Urol·2023·Human·PubMed →
Pharmacotherapy for female sexual dysfunctions (FSDs): what is on the market and where is this field heading?
Nappi RE, Tiranini L, Cucinella L et al.
Expert Opin Pharmacother·2023·Animal·PubMed →
Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide.
Simon JA, Kingsberg SA, Portman D et al.
J Womens Health (Larchmt)·2022·Human·Sexual Health·PubMed →
Safety Profile of Bremelanotide Across the Clinical Development Program.
Clayton AH, Kingsberg SA, Portman D et al.
J Womens Health (Larchmt)·2022·Human·Sexual Health·PubMed →
Finding Our Way From the Bench to the Bedside: The Ethos, Logos, and Pathos of Biomedical Research.
Kim NN
Sex Med Rev·2022·Animal·PubMed →
Effect of bremelanotide on body weight of obese women: Data from two phase 1 randomized controlled trials.
Spana C, Jordan R, Fischkoff S
Diabetes Obes Metab·2022·Animal·Weight Loss·PubMed →
Failure of a Meta-analysis: A Commentary on Glen Spielmans's "Re-Analyzing Phase III Bremelanotide Trials for 'Hypoactive Sexual Desire Disorder in Women'".
Kingsberg SA, Clayton AH, Portman D et al.
J Sex Res·2021·Human·Sexual Health·PubMed →
Re-Analyzing Phase III Bremelanotide Trials for "Hypoactive Sexual Desire Disorder" in Women.
Spielmans GI
J Sex Res·2021·Human·PubMed →
The Patient Experience of Premenopausal Women Treated with Bremelanotide for Hypoactive Sexual Desire Disorder: RECONNECT Exit Study Results.
Koochaki P, Revicki D, Wilson H et al.
J Womens Health (Larchmt)·2021·Human·Sexual Health·PubMed →
Psychometric validation of the Female Sexual Distress Scale-Desire/Arousal/Orgasm.
Derogatis LR, Revicki DA, Rosen RC et al.
J Patient Rep Outcomes·2021·Animal·PubMed →
Structural insights into ligand recognition and activation of the melanocortin-4 receptor.
Zhang H, Chen LN, Yang D et al.
Cell Res·2021·Animal·PubMed →
LC-HRMS characterization of the skin pigmentation and sexual enhancers melanotan II and bremelanotide sold on the black market of performance and image enhancing drugs.
Mestria S, Odoardi S, Frison G et al.
Drug Test Anal·2021·Animal·PubMed →
Reliability and validity of the elements of desire questionnaire in premenopausal women with hypoactive sexual desire disorder.
Revicki DA, Althof SE, Derogatis LR et al.
J Patient Rep Outcomes·2020·Animal·PubMed →
Female Hypoactive Sexual Desire Disorder: A Practical Guide to Causes, Clinical Diagnosis, and Treatment.
Kingsberg SA, Simon JA
J Womens Health (Larchmt)·2020·Animal·Sexual Health·PubMed →
Ultra-sensitive quantification of the therapeutic cyclic peptide bremelanotide utilizing UHPLC-MS/MS for evaluation of its oral plasma pharmacokinetics.
Sauter M, Uhl P, Burhenne J et al.
J Pharm Biomed Anal·2020·Animal·PubMed →
New Drugs 2020, part 2.
Hussar DA
Nursing·2020·Animal·PubMed →
Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.
Kingsberg SA, Clayton AH, Portman D et al.
Obstet Gynecol·2019·Human·PubMed →
Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide.
Althof S, Derogatis LR, Greenberg S et al.
J Sex Med·2019·Human·Sexual Health·PubMed →
Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder.
Simon JA, Kingsberg SA, Portman D et al.
Obstet Gynecol·2019·Animal·PubMed →
Boosting Female Sexual Response by RECONNECTing the Dots.
Carson SA
Obstet Gynecol·2019·Animal·Sexual Health·PubMed →
New Drug for Hypoactive Sexual Desire Disorder in Premenopausal Women.
Aschenbrenner DS
Am J Nurs·2019·Animal·Sexual Health·PubMed →
What are the challenges in prescribing pharmacotherapy for female sexual dysfunctions?
Nappi RE, Gardella B
Expert Opin Pharmacother·2019·Animal·PubMed →
Phase I Randomized Placebo-controlled, Double-blind Study of the Safety and Tolerability of Bremelanotide Coadministered With Ethanol in Healthy Male and Female Participants.
Clayton AH, Lucas J, DeRogatis LR et al.
Clin Ther·2017·Human·PubMed →
Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide.
White WB, Myers MG, Jordan R et al.
J Hypertens·2017·Human·PubMed →
Sexual arousal: Sex matters.
Petherick A
Nature·2017·Animal·Neuroprotection, Sexual Health·PubMed →
Re: Bremelanotide for Female Sexual Dysfunctions in Premenopausal Women: A Randomized, Placebo-Controlled Dose-Finding Trial.
Seftel AD
J Urol·2016·Human·PubMed →
Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial.
Clayton AH, Althof SE, Kingsberg S et al.
Womens Health (Lond)·2016·Human·PubMed →
Hypoactive sexual desire disorder in women: treatment options beyond testosterone and approaches to communicating with patients on sexual health.
Lodise NM
Pharmacotherapy·2013·Human·PubMed →
[2013 annual meeting of the International Society for the Study of Women's Sexual Health (ISSWSH), 28 February-3 March 2013, New Orleans, Louisiana, USA. State of pharmacologial research in Women's Sexual Medicine: From testosterone to bremelatonide].
Buvat J
Gynecol Obstet Fertil·2013·Animal·PubMed →
Melanotan II injection resulting in systemic toxicity and rhabdomyolysis.
Nelson ME, Bryant SM, Aks SE
Clin Toxicol (Phila)·2012·Animal·PubMed →
Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study.
Safarinejad MR, Hosseini SY
J Urol·2008·Human·PubMed →
RETRACTED: Evaluation of the safety and efficacy of bremelanotide, a melanocortin receptor agonist, in female subjects with arousal disorder: a double-blind placebo-controlled, fixed dose, randomized study.
Safarinejad MR
J Sex Med·2008·Human·Sexual Health·PubMed →
Gateways to clinical trials.
Tomillero A, Moral MA
Methods Find Exp Clin Pharmacol·2008·Animal·PubMed →
Gateways to clinical trials.
Tomillero A, Moral MA
Methods Find Exp Clin Pharmacol·2008·Animal·PubMed →
Pharmacological profiling of neuropeptides on rabbit vaginal wall and vaginal artery smooth muscle in vitro.
Aughton KL, Hamilton-Smith K, Gupta J et al.
Br J Pharmacol·2008·Animal·PubMed →
An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist.
Diamond LE, Earle DC, Heiman JR et al.
J Sex Med·2006·Human·Sexual Health·PubMed →
Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response.
Diamond LE, Earle DC, Garcia WD et al.
Urology·2005·Human·Sexual Health·PubMed →
Gateways to clinical trials.
Bayés M, Rabasseda X, Prous JR
Methods Find Exp Clin Pharmacol·2004·Human·PubMed →
Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra.
Rosen RC, Diamond LE, Earle DC et al.
Int J Impot Res·2004·Human·Sexual Health·PubMed →
Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction.
Diamond LE, Earle DC, Rosen RC et al.
Int J Impot Res·2004·Human·Sexual Health·PubMed →
PT-141: a melanocortin agonist for the treatment of sexual dysfunction.
Molinoff PB, Shadiack AM, Earle D et al.
Ann N Y Acad Sci·2003·Human·Sexual Health, Neuroprotection·PubMed →